Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?

NetraMark: Smart AI for drugs and markets

Healthtech company NetraMark Holdings is establishing itself as a pioneer in the pharmaceutical industry and offers investors exciting growth potential. With its NetraAI technology, the Company is addressing one of the industry's biggest challenges: only 12% of drug candidates receive FDA approval, with average development costs of USD 2.6 billion and research periods of 10 to 15 years.

Especially in research on diseases of the central nervous system (CNS) (15% approval despite 51.1% Phase 3 success) and in oncology (3.4% approval rate), the hurdles for a successful drug are immense. NetraMark could provide a smart solution here that increases the efficiency and success of research-based pharmaceutical companies such as Bayer and Novo Nordisk.

The core element, NetraAI, is trained to analyze small, study-specific data sets. Instead of relying on external data sources, which can lead to altered results and thus increase the error rate, NetraAI uses only the data of the respective pharmaceutical company. At the ISCTM conference in early March, NetraMark presented impressive results: In cases of major depressive disorder (MDD), NetraAI increases model accuracy by up to 40% compared to traditional methods, such as a 28% higher hit accuracy in the CAN-BIND study trial with the active ingredient escitalopram.

In schizophrenia (CATIE study), NetraMark AI accurately identified patient subgroups – such as those with moderate negative symptoms and hallucinations – that respond better to perphenazine. Thanks to a topology-based algorithm, NetraMark breaks down the small data sets into explainable subgroups, reduces placebo effects, and increases specificity by 51%. "Our technology can significantly improve clinical outcomes," explains Dr. Joseph Geraci, CTO and CSO. Inappropriate data is deliberately omitted to avoid shifting and to sharpen the significance of the respective study. This increases the success rate and the chance of market approval.

For investors, this is a strong argument: NetraMark could significantly reduce the costs and risks of drug development for research-based pharmaceutical companies. With CAD 1.16 million from capital measures, the Company shows corresponding dynamism. The technology is also aligned with FDA guidelines – a foundation for continuous growth that could make NetraMark an attractive investment in the exciting healthcare AI segment.

Bayer: Targeted cancer therapy with future prospects

Bayer is launching an offensive in precision oncology, which could pay off for investors. On March 4, 2025, the Company launched the global Phase II panSOHO study with the active ingredient BAY 2927088, a promising treatment for patients with metastatic or inoperable tumors driven by HER2 mutations. Whether uterus, bowel or gallbladder – there are often few effective treatments for cancer of these organs in the body. Bayer is now pursuing a targeted strategy that strengthens research and market opportunities in equal measure.

Precision medicine aims to customize treatments to fit each patient's individual needs and characteristics. DNA testing is often used to tailor the appropriate therapy for the individual. According to BioSpace, the market for precision oncology will continue to grow: in 2024, it was worth USD 121 billion and is expected to reach USD 312 billion by 2034 – an annual growth rate of almost 10%.

The panSOHO study brings together patients with different tumor types who have one thing in common – the genetic HER2 mutation. BAY 2927088 targets the diseased cells without excessively affecting the healthy ones, thus promising fewer side effects. "We want to open up new avenues for patients with few options," says Dr. Christian Rommel, Head of Research and Development at Bayer Pharmaceuticals. The results could revolutionize cancer treatment.

For investors, this presents an opportunity: Bayer is driving forward a field that urgently needs progress. With revenue of EUR 47.6 billion expected in 2023 and a broad portfolio of approved drugs and development projects, the Company is in a solid position. BAY 2927088 could be the next big breakthrough in cancer therapy.

Novo Nordisk: Progress with Obesity Treatment Successor CagriSema

Novo Nordisk announced a success this week: The Phase III REDEFINE 2 study of the obesity successor drug CagriSema has finally achieved its primary goal. In this study, patients who were overweight or had type 2 diabetes and who weighed an average of 102 kg lost significantly more weight than the placebo control group after 68 weeks. However, the result falls short of high expectations – a point investors should not overlook.

CagriSema combines the active ingredients Cagrilintide and Semaglutide, known as Wegovy. After 68 weeks, a weight loss of 15.7% is observed when all participants stick to the treatment, compared to only 3.1% in the placebo group. Without this assumption, the value is 13.7%, while the placebo group achieves 3.4%. Almost 90% of treated patients lose at least 5% of their weight, compared to 30% in the placebo group. "The results show a clear superiority," says Martin Holst Lange, head of development at Novo Nordisk. However, the Company hopes for a 25% weight loss – a target that will not be achieved even in the REDEFINE 1 study.

The study allows for flexible dose adjustments, and 61.9% of the participants use the maximum dose. Side effects, especially gastrointestinal, remain mostly mild. Novo Nordisk plans to file for approval in 2026. Despite the progress, the stock dropped 9.4%, following a 27.3% loss over the past three months – while the industry continues to grow. Nevertheless, the Company remains a strong player in the healthcare sector.

NetraMark offers a solution for the pharmaceutical industry with its proprietary NetraAI software: the AI analyzes small data sets, increasing model accuracy by 40% for depression, for example, and specificity by 51% for schizophrenia. This can significantly reduce R&D costs and risks in areas such as CNS and oncology. With CAD 1.16 million from capital measures, the Company is showing growth ambitions. With its Phase II panSOHO study, Bayer is focusing on precision medicine to combat tumors with HER2 mutations. The precision oncology strategy aims at personalized therapies in a market expected to grow to USD 312 billion by 2034. Novo Nordisk reports success this week with obesity blocker CagriSema in its REDEFINE 2 study: participants achieved a weight loss of 15.7% after 68 weeks for obesity and type 2 diabetes. NetraMark appears interesting for growth investors as it offers significant growth potential in the healthcare AI sector. Bayer offers a good balance of stability and future prospects in the oncology market, making it an appealing case for conservative investors. Novo Nordisk remains a strong player but is struggling with unmet targets.